C3 Glomerulopathy
📧 Sign up to get email alerts when something new happens for C3 Glomerulopathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Chinese Adults With Kidney Disease [Phase 2]
ADARx Pharmaceuticals is conducting a Phase 2 trial in Chinese adults with immunoglobulin A nephropathy, C3 glomerulopathy, or immune comple…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease [Phase 2]
Phase 2 clinical trial evaluating ADX-038 for complement-mediated kidney disease, including IgA nephropathy and C3 glomerulopathy, is curren…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy [Phase 1]
A Phase 1 clinical trial update on CPV-104 evaluating safety, tolerability, and pharmacokinetics in healthy adults and individuals with C3 g…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN [Phase 3]
Phase 3 trial update on iptacopan for C3 glomerulopathy and immune-complex-mediated membranoproliferative glomerulonephritis; recruitment is…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Fabhalta Capsules Specified Drug-use Survey
A recruiting clinical trial evaluating Fabhalta Capsules for C3 glomerulopathy.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Study of NM8074 in Adult C3 Glomerulopathy Patients [Phase 1, Phase 2]
This clinical trial update reports a Phase 1/2 study of NM8074 for adult patients with C3 glomerulopathy, noting that the study is not yet r…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis [Phase 3]
An open-label, nonrandomized multicenter extension study to assess the long-term safety and efficacy of Pegcetacoplan in participants with C…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. [Phase 3]
A Phase 3 study evaluating the efficacy and safety of iptacopan in C3 glomerulopathy is currently recruiting. The sponsor listed is Novartis…
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 [Phase 2]
Omeros' Phase 2 safety study of OMS721 in immunoglobulin A nephropathy, lupus nephritis, membranous nephropathy, and C3 glomerulopathy inclu…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: New Analytic Tools for aHUS and C3G Diagnosis [NA]
An active-not-recruiting trial from Mario Negri Institute is evaluating new analytic tools to improve the diagnosis of atypical hemolytic ur…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy
This document reports an update on a clinical trial testing iptacopan in Korean patients with Paroxysmal Nocturnal Hemoglobinuria or C3 glom…
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: CHART-C3G/CLNP023B12011
Novartis' CHART-C3G trial is evaluating iptacopan (LNP023) for C3 glomerulopathy; the study is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2025-12-16Clinical Trial Update: Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease [Phase 1, Phase 2]
This document reports the completion of a Phase 1/2 study of ARO-C3 from Arrowhead Pharmaceuticals in adults, including healthy volunteers a…
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: Managed Access Programs for LNP023, Iptacopan
This clinical trial update notes the availability of managed access programs for iptacopan (LNP023) for patients with C3 glomerulopathy and …
-
CLINICAL_TRIALS approval · 2025-11-06Clinical Trial Update: C3G/Primary IC-MPGN EAP
Apellis' pegylated C3 inhibitor pegcetacoplan has gained marketing approval for C3 glomerulopathy and immune complex–mediated MPGN as part o…
-
CLINICAL_TRIALS trial_result · 2025-08-06Clinical Trial Update: Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis [Phase 3]
Phase 3 trial evaluating pegcetacoplan for C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis has completed with …
-
CLINICAL_TRIALS research · 2025-07-15Clinical Trial Update: Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN [Phase 2]
A Phase 2 trial evaluating the safety and efficacy of OMS906 in C3 glomerulopathy and idiopathic immune complex-mediated glomerulonephritis …
-
CLINICAL_TRIALS research · 2025-06-22Clinical Trial Update: Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy [Phase 2]
Phase 2 trial evaluating aliskiren (a renin inhibitor) versus enalapril in C3 glomerulopathy and related glomerulonephritis, currently recru…
-
CLINICAL_TRIALS trial_result · 2025-06-19Clinical Trial Update: Home Reported Outcomes in C3G Study
This clinical trial update indicates a study evaluating home-reported outcomes in patients with C3 glomerulopathy is currently recruiting. I…
-
CLINICAL_TRIALS withdrawal · 2025-04-20Clinical Trial Update: A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G [Phase 2]
Phase 2 trial of ADX-097 for IgA nephropathy, lupus nephritis, and C3 glomerulopathy has been withdrawn.
-
CLINICAL_TRIALS research · 2025-02-28Clinical Trial Update: Clinical Outcomes of C3 Glomerulopathy and IC-MPGN in Russia: Hybrid Retrospective - Prospective Study
Clinical trial update describing a hybrid retrospective-prospective study of outcomes in C3 glomerulopathy and immune complex-mediated membr…
-
CLINICAL_TRIALS trial_result · 2025-02-07Clinical Trial Update: Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN [Phase 2]
Phase 2 trial assessing pegcetacoplan for post-transplant recurrence of C3 glomerulopathy and immune complex-mediated MPGN has completed wit…
-
CLINICAL_TRIALS research · 2025-01-22Clinical Trial Update: A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases [Phase 2]
A Phase 2 clinical trial of SGB-9768 for complement-mediated kidney diseases, including IgA nephropathy and C3 glomerulopathy, has not yet s…
-
CLINICAL_TRIALS trial_result · 2022-10-14Clinical Trial Update: Controlled Trial Evaluating Avacopan in C3 Glomerulopathy [Phase 2]
Amgen completed a controlled Phase 2 trial of avacopan in C3 glomerulopathy. The study results were posted in October 2022.
-
CLINICAL_TRIALS trial_result · 2022-08-11Clinical Trial Update: A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 [Phase 2]
Phase 2 proof-of-concept trial for a 12-month treatment in C3 glomerulopathy-related conditions (C3 Glomerulonephritis/IC-MPGN) with ACH-014…